Zepbound brings more weight loss than Wegovy: Drugmaker
Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical trial results. Zepound manufacturer Eli Lilly released results from
Weight-loss meds go head-to-head in new study. One was significantly more effective, drugmaker says
In the first head-to-head test, people using Eli Lilly’s Zepbound lost just over 50 pounds while those using competitor Novo Nordisk’s Wegovy shed more than 33 pounds
Zepbound leads to more weight loss than Wegovy, new study finds
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Ozempic Isn't the No. 1 Treatment for Weight Loss, New Study Finds
If you’ve been debating starting a weight-loss treatment like tirzepatide or semaglutide, you’re going to want to listen closely. In a new trial conducted by Eli Lilly, its tirzepatide injection for weight loss,
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight loss is most effective at helping people lose more weight in less time. Zepbound,
Eli Lilly claims superiority of its weight-loss drug Zepbound after clinical trial
Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative areas of the pharmaceutical indus
Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.
Zepbound Tops Wegovy for Weight Loss in Eli Lilly Study
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nor
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.
In new trial, Zepbound bests Wegovy for weight loss
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.
Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.
Biden proposes new rule for weight-loss drugs to be covered by Medicare, Medicaid
The Biden administration is proposing a new rule to significantly expand the coverage of weight-loss drugs for Americans on ...
Dog the Bounty Hunter’s Daughter Bonnie Chapman Learned to Avoid Carbs 'Every Single Meal' on Popular Weight Loss Drug
"A lot of the things that I found that I really liked are not healthy for me," said the 25-year-old, who is taking ...
The American Journal of Managed Care9d
FDA Advised to Update Labels on GLP-1 Weight-Loss Drugs
In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight ...